Skip to Content
Merck
All Photos(1)

Key Documents

924202

Sigma-Aldrich

5-Amino-Thalidomide

≥95%

Synonym(s):

5-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, C5 Pomalidomide, PROTAC® research ligand

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C13H11N3O4
CAS Number:
Molecular Weight:
273.24
MDL number:
UNSPSC Code:
12352101
NACRES:
NA.22

ligand

thalidomide

Quality Level

Assay

≥95%

form

powder

SMILES string

O=C1C2=CC=C(N)C=C2C(=O)N1C3C(=O)NC(=O)CC3

InChI

1S/C13H11N3O4/c14-6-1-2-7-8(5-6)13(20)16(12(7)19)9-3-4-10(17)15-11(9)18/h1-2,5,9H,3-4,14H2,(H,15,17,18)

InChI key

IICWMVJMJVXCLY-UHFFFAOYSA-N

Application

5-Amino-Thalidomide is a derivative of the Cereblon (CRBN)-binding ligand thalidomide. 5-Amino-Thalidomide can be used to bind the CRBN E3 ubiquitin ligase in targeted protein degradation research or in the synthesis
of protein degraders with a C5 exit vector. This was previously listed under AMBH2D6FF88F.

Related Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Browse our growing synthesis and research tools: Protein Degrader Building Blocks

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Product No.
Description
Pricing

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

George M Burslem et al.
ChemMedChem, 13(15), 1508-1512 (2018-06-06)
The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years. Recently, their use as E3 ligase recruiting elements for small-molecule-induced protein degradation has led to a resurgence in interest in
Binbin Cheng et al.
European journal of medicinal chemistry, 199, 112377-112377 (2020-05-11)
Novel resorcinol diphenyl ether-based PROTACs (PROteolysis TArgeting Chimeras) were designed and evaluated for their inhibitory activity against the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway and their ability to degrade PD-L1 protein. Most of the compounds displayed excellent inhibitory
Alexandru D Buhimschi et al.
Biochemistry, 57(26), 3564-3575 (2018-06-01)
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service